Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: J Cancer Surviv. 2019 Jul 24;13(5):730–738. doi: 10.1007/s11764-019-00791-9

Table 2.

Comparison of age- and sex-stratified cumulative incidence to incidence at 2.7 years follow-up of human papillomavirus (HPV) vaccine initiation among childhood and adolescent and young adult (AYA) cancer survivors after therapy

Age at eligibility Cumulative incidence Incidence at 2.7 years follow-up
Female
 11–17 years 48.1% 29.3%
 18–26 years 6.2% 5.3%
Male
 11–17 years 29.2% 13.7%
 18–26 years 2.0% 1.1%